Thrombospondin-1 Inhibits VEGF Receptor-2 Signaling by Disrupting Its Association with CD47*
暂无分享,去创建一个
[1] D. Roberts,et al. Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. , 2010, Cardiovascular research.
[2] S. P. Herbert,et al. Ligand‐Stimulated VEGFR2 Signaling is Regulated by Co‐Ordinated Trafficking and Proteolysis , 2010, Traffic.
[3] P. Rochaix,et al. Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer , 2009, Proceedings of the National Academy of Sciences.
[4] P. Bornstein,et al. Thrombospondins function as regulators of angiogenesis , 2009, Journal of Cell Communication and Signaling.
[5] H. Dvorak,et al. Thrombospondin‐1 modulates vascular endothelial growth factor activity at the receptor level , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[6] A. Grothey,et al. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules , 2009, Nature Reviews Clinical Oncology.
[7] B. Hopkins,et al. Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina. , 2009, American journal of physiology. Heart and circulatory physiology.
[8] T. Byzova,et al. Cooperation between integrin ανβ3 and VEGFR2 in angiogenesis , 2009, Angiogenesis.
[9] D. Roberts,et al. Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies , 2009, Nature Reviews Cancer.
[10] D. Mosher,et al. Differential Interactions of Thrombospondin-1, -2, and -4 with CD47 and Effects on cGMP Signaling and Ischemic Injury Responses* , 2009, Journal of Biological Chemistry.
[11] S. Wedge,et al. Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy , 2008, Clinical Cancer Research.
[12] D. Roberts,et al. Gene Silencing of CD47 and Antibody Ligation of Thrombospondin-1 Enhance Ischemic Tissue Survival in a Porcine Model: Implications for Human Disease , 2008, Annals of surgery.
[13] D. Roberts,et al. Thrombospondin-1: a physiological regulator of nitric oxide signaling. , 2008, Cellular and molecular life sciences : CMLS.
[14] D. Wink,et al. Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. , 2008, Blood.
[15] D. Wink,et al. Blockade of Thrombospondin-1-CD47 Interactions Prevents Necrosis of Full Thickness Skin Grafts , 2008, Annals of surgery.
[16] N. Ferrara,et al. VEGF inhibition: insights from preclinical and clinical studies , 2008, Cell and Tissue Research.
[17] Kenneth P. Roos,et al. Autocrine VEGF Signaling Is Required for Vascular Homeostasis , 2007, Cell.
[18] Julia Fukuyama,et al. Thrombospondin-1 Inhibits Nitric Oxide Signaling via CD36 by Inhibiting Myristic Acid Uptake* , 2007, Journal of Biological Chemistry.
[19] D. Wink,et al. Increasing Survival of Ischemic Tissue by Targeting CD47 , 2007, Circulation research.
[20] J. Lawler,et al. Thrombospondin‐1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor‐related protein‐1 (LRP‐1) , 2007, Journal of cellular physiology.
[21] D. Discher,et al. Phylogenetic Divergence of CD47 Interactions with Human Signal Regulatory Protein α Reveals Locus of Species Specificity , 2007, Journal of Biological Chemistry.
[22] M. Shibuya. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. , 2006, Journal of biochemistry and molecular biology.
[23] D. Wink,et al. CD47 Is Necessary for Inhibition of Nitric Oxide-stimulated Vascular Cell Responses by Thrombospondin-1* , 2006, Journal of Biological Chemistry.
[24] Ha Won Kim,et al. IQGAP1 Mediates VE-Cadherin–Based Cell–Cell Contacts and VEGF Signaling at Adherence Junctions Linked to Angiogenesis , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[25] F. Orsenigo,et al. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments , 2006, The Journal of cell biology.
[26] D. Wink,et al. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[27] E. Smart,et al. Myristic Acid Stimulates Endothelial Nitric-oxide Synthase in a CD36- and an AMP Kinase-dependent Manner* , 2005, Journal of Biological Chemistry.
[28] D. Ingber,et al. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by β1 integrins , 2005, The Journal of cell biology.
[29] J. Folkman. Endogenous angiogenesis inhibitors , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[30] David D Roberts,et al. &agr;4&bgr;1 Integrin Mediates Selective Endothelial Cell Responses to Thrombospondins 1 and 2 In Vitro and Modulates Angiogenesis In Vivo , 2004, Circulation research.
[31] .. C.N.Fokunang,et al. Advancement in Genetic Modification Technologies Towards Disease Resistance and Food Crop Production , 2004 .
[32] R. Hebbel,et al. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis , 2004, Angiogenesis.
[33] L. Maile,et al. Integrin-Associated Protein Binding Domain of Thrombospondin-1 Enhances Insulin-Like Growth Factor-I Receptor Signaling in Vascular Smooth Muscle Cells , 2003, Circulation research.
[34] N. Ortéga,et al. Extracellular matrix‐bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[35] H. Krutzsch,et al. Regulation of Integrin Function by CD47 Ligands , 2002, The Journal of Biological Chemistry.
[36] A. Joachimiak,et al. Crystal structure of the TSP-1 type 1 repeats , 2002, The Journal of cell biology.
[37] I. Shiojima,et al. Role of Akt Signaling in Vascular Homeostasis and Angiogenesis , 2002, Circulation research.
[38] J. Lawler,et al. Thrombospondin‐1 as an endogenous inhibitor of angiogenesis and tumor growth , 2002, Journal of cellular and molecular medicine.
[39] M. Shibuya,et al. A single autophosphorylation site on KDR/Flk‐1 is essential for VEGF‐A‐dependent activation of PLC‐γ and DNA synthesis in vascular endothelial cells , 2001, The EMBO journal.
[40] E. Brown,et al. Integrin-associated protein (CD47) and its ligands. , 2001, Trends in cell biology.
[41] D. Mosher,et al. Physical Characterization of the Procollagen Module of Human Thrombospondin 1 Expressed in Insect Cells* , 2000, The Journal of Biological Chemistry.
[42] M. Iruela-Arispe,et al. Cell Contact–dependent Activation of α3β1 Integrin Modulates Endothelial Cell Responses to Thrombospondin-1 , 2000 .
[43] A. Zeiher,et al. Phosphorylation of the endothelial nitric oxide synthase at Ser‐1177 is required for VEGF‐induced endothelial cell migration , 2000, FEBS letters.
[44] O. Volpert,et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 , 2000, Nature Medicine.
[45] H. Krutzsch,et al. Identification of an α3β1 Integrin Recognition Sequence in Thrombospondin-1* , 1999, The Journal of Biological Chemistry.
[46] R. Busse,et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation , 1999, Nature.
[47] B. Herman,et al. Quantitative fluorescence resonance energy transfer measurements using fluorescence microscopy. , 1998, Biophysical journal.
[48] G. Garcı́a-Cardeña,et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. , 1997, The Journal of clinical investigation.
[49] David W. Dawson,et al. CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells , 1997, The Journal of cell biology.
[50] D. Roberts,et al. Purification of thrombospondin from human platelets , 1994 .
[51] S. Liu,et al. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. , 1993, The American journal of physiology.
[52] J. Winer,et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. , 1992, The Journal of biological chemistry.
[53] M. L. Le Beau,et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[54] L. Liotta,et al. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor , 1990, The Journal of cell biology.
[55] P. Bagavandoss,et al. Specific inhibition of endothelial cell proliferation by thrombospondin. , 1990, Biochemical and biophysical research communications.